Canaccord Genuity analyst Richard Close maintained a Buy rating on Teladoc (TDOC) yesterday and set a price target of $130.00. The company’s shares closed last Tuesday at $157.33, close to its 52-week high of $176.40.
According to TipRanks.com, Close is a 5-star analyst with an average return of 10.5% and a 56.7% success rate. Close covers the Technology sector, focusing on stocks such as Castlight Health, Health Catalyst, and HealthStream.
Teladoc has an analyst consensus of Moderate Buy, with a price target consensus of $136.25, which is a -13.0% downside from current levels. In a report issued on April 13, Leerink Partners also initiated coverage with a Buy rating on the stock with a $180.00 price target.
See today’s analyst top recommended stocks >>
Based on Teladoc’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $156 million and GAAP net loss of $19.04 million. In comparison, last year the company earned revenue of $123 million and had a GAAP net loss of $24.88 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. Its portfolio of services and solutions covers medical subspecialties from non-urgent, episodic needs like flu and upper respiratory infections, to chronic, complicated medical conditions like cancer and congestive heart failure. The company was founded on June 13, 2002 by George Byron Brooks and is headquartered in Purchase, NY.
